Us Pharmaceutical And Biotech Correspondent
Oliver Barnes is a US pharmaceutical and biotech correspondent at the Financial Times. He focuses on scientific innovation, blockbuster drugs, and access to healthcare, while also having experience in covering finance, investment, and real estate. Oliver's work has been featured in notable publications including The Irish Times, Financial Post, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Oliver Barnes covers a variety of topics related to the business sector, including investments, gambling, restaurants, and media. He also shows interest in sports and entertainment news. His articles often include private sector announcements as well as government announcements and press releases.
To effectively reach out to Oliver with pitches or insights, consider offering exclusive information about industry trends or market movements within the UK or providing expert commentary on developments affecting businesses in these sectors. If you have access to insider knowledge about companies' financial performances or strategic moves in the UK's business landscape, your pitch is likely to resonate with him.
When reaching out regarding sporting events or entertainment news related to businesses (e.g., sponsorships), ensure that your content aligns with his coverage focus on the national level within the United Kingdom.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Media mogul says ‘we didn’t feel the mix was coming together in the way we had hoped’ after going public with offer in June
By: Oliver Barnes
Talks between web domain provider and Gen Digital at early stage but could allow acquirer to broaden its business beyond cyber security
By: Kaye Wiggins, Oliver Barnes, Suzi Ring, Sujeet Indap
One of America’s most prestigious firms is in turmoil as a series of departures prompts talk of a merger
By: Oliver Barnes, Aaron Kirchfeld, Florian Müller
Size of premium may increase pressure on management and biggest shareholder
By: Oliver Barnes, Sujeet Indap
The recruitment is a rare move by the firm to poach talent from a rival and comes after the departure of a top litigator and five other partners
By: Ashley Armstrong, Ivan Levingston, Oliver Barnes, Alexandra Heal
Petrol station empire had filed for a listing in New York under its Cumberland Farms brand with the aim of raising about $1bn at a $9bn valuation
By: James Fontanella-Khan, Aaron Kirchfeld, Oliver Barnes
Acquisition would be French group’s largest and expand its industrial software capability
By: Oliver Barnes, Ivan Levingston
Interest rate rises, AI anxiety and midterm elections cool animal spirits after record-breaking start to the year
By: Oliver Barnes, Kaye Wiggins, Suzi Ring
World’s highest-grossing law firm with $10.6bn in 2025 revenue volunteered data for leading industry profit ranking
By: Oliver Barnes, James Fontanella-Khan, Arash Massoudi, Gregory Meyer
Starbucks has explored a takeover of Chipotle Mexican Grill, in an ambitious gambit to unite two of America's best-known brands in a deal
